Advances in EGFR+ NSCLC

Continue With

Related Topics

Jul 05 2026

Targeted Therapies in NSCLC

O. GautschiJ. NaidooN. GirardZ. Piotrowska

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Jul 05 2026

The International Lung Cancer Summit 2026

The International Lung Cancer Summit returns on 13 November 2026 – on site in Lausanne and streamed online. A one-day programme of practice-changing lung cancer debates, chaired by Solange Peters and Alfredo ...

U. MalapelleD. PlanchardG. MountziosS. Patel

Jul 05 2026

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A recorded symposium from ESMO Congress 2026, tracing small-cell lung cancer treatment from immunotherapy standards to the emerging era of DLL3 T-cell engagers. The recording is published here after the ...

M. ReckS. PetersG. MountziosN. Reguart

Apr 15 2026

TARGETED THERAPIES

Metastatic NSCLCTargeted Therapies

Targeted Therapies in Metastatic NSCLC: Reshaping First-Line Choice

Five next-generation TKIs have rewritten first-line choice in driver-positive metastatic NSCLC. This update distils which biomarker matters, when CNS coverage drives the pick, and where the field is heading ...

Mar 22 2026

ADCs

BiomarkersSCLCADCs

ADCs in Small Cell Lung Cancer: An Emerging Class

Antibody-drug conjugates are arriving in SCLC after a decade of failed cytotoxics. Three platforms — DLL3, B7-H3, and SEZ6 — now have phase-2 readouts. This update...